Objectives: The primary purpose of this study was to investigate the in vitro and in vivo effect of survivin interference RNA (siRNA) on non-small cell lung cancer. Methods: Lentivirus was used as a vector to transfer siRNA into human lung cancer A549 cells. The proliferation of the cancer cells was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The lentivirus-mediated siRNA was also injected into the transplanted A549 tumor tissues in mice. Tumour growth was assessed after 11 injections over a period of 21 days. Results: Compared with the placebo and the blank lentiviral vector groups, the siRNA treatment group had reduced cell growth rate following 4 days of the treatment (P<0.01). The average size of the transplanted A549 tumours in the siRNA treatment group (0.75±0.16 cm3, n=8) was smaller than in the placebo (2.09±0.22 cm3, n=6) or the blank lentivrial vector groups (1.89±0.18 cm3, n=6) (P<0.01). The tumour growth inhibition rate in the siRNA groups was 46.1%. Conclusion: Lentivirus-mediated siRNA therapy inhibits the growth of human lung cancer cells in vitro. The siRNA therapy also suppresses the growth of the transplanted lung cancer in mice.
|Number of pages||7|
|Journal||Clinical and Investigative Medicine|
|Publication status||Published - 2009|